Harrow Inc
HROW34.930USD
+3.560+11.35%
Handelsschluss 07/11, 16:00（ET）Kurse um 15 Minuten verzögert
1.25BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Harrow Inc Unternehmen
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Unternehmensinformationen
BörsenkürzelHROW
Name des UnternehmensHarrow Inc
IPO-datumFeb 08, 2013
Gegründet am2006
CEOMr. John P. Saharek
Anzahl der mitarbeiter382
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 08
Addresse1A Burton Hills Blvd
StadtNASHVILLE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl37215
Telefon16157334731
Websitehttps://www.harrow.com/
BörsenkürzelHROW
IPO-datumFeb 08, 2013
Gegründet am2006
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
Aktionäre
Aktionäre
Anteil
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
23.15%
Hedge Fund
18.11%
Individual Investor
15.07%
Investment Advisor
12.93%
Research Firm
2.04%
Pension Fund
0.45%
Bank and Trust
0.33%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
Other
27.83%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
340
26.58M
72.44%
-3.00M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
2023Q1
246
23.86M
79.81%
+1.57M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Opaleye Management Inc.
3.94M
10.72%
-4.80K
-0.12%
Jun 04, 2025
Baum (Mark L)
2.60M
7.08%
+461.94K
+21.61%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.27M
6.2%
-1.07K
-0.05%
Mar 31, 2025
Private Capital Management
1.89M
5.15%
+195.64K
+11.54%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
5.07%
-6.65K
-0.36%
Mar 31, 2025
Kaufman (Daniel)
1.68M
4.59%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
956.84K
2.61%
+49.80K
+5.49%
Mar 31, 2025
State Street Global Advisors (US)
786.48K
2.14%
-41.22K
-4.98%
Mar 31, 2025
Boll (Andrew R)
777.84K
2.12%
+209.75K
+36.92%
Apr 21, 2025
Geode Capital Management, L.L.C.
774.08K
2.11%
+52.97K
+7.35%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
SPDR S&P Pharmaceuticals ETF
1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.76%
iShares U.S. Pharmaceuticals ETF
0.48%
First Trust Small Cap Growth AlphaDEX Fund
0.4%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Fidelity Small-Mid Multifactor ETF
0.09%
First Trust Multicap Growth Alphadex Fund
0.07%
Mehr Anzeigen
SPDR S&P Pharmaceuticals ETF
Anteil1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil0.76%
iShares U.S. Pharmaceuticals ETF
Anteil0.48%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.4%
iShares Micro-Cap ETF
Anteil0.19%
ProShares Ultra Nasdaq Biotechnology
Anteil0.13%
Invesco Nasdaq Biotechnology ETF
Anteil0.11%
Vanguard US Momentum Factor ETF
Anteil0.1%
Fidelity Small-Mid Multifactor ETF
Anteil0.09%
First Trust Multicap Growth Alphadex Fund
Anteil0.07%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
